Neurocysticercosis prevalence estimates often are based on serosurveys. However, assessments of Tae-nia solium seropositivity durability in patients with vari-ous neurocysticercosis types are lacking. We optimized a triplex serologic ELISA by using synthetic GP50, T24H, and Ts18var3 antigens for T. solium. We used that as-say to test sequential serologic responses over sever-al years after neurocysticercosis cure in 46 patients, 9 each with parenchymal or ventricular neurocysticercosis and 28 with subarachnoid disease. Triplex results were concordant with 98% of positive and 100% of negative enzyme-linked immunoelectrotransfer blots. Eight years after neurocysticercosis cure, 11.1% of patients with pa-renchymal, 47.3% with subarachnoid, and 41.7% with ventricular disease were still seropositive. Median time to seroreversion after cure in this cohort in a T. solium nonendemic area was 2 years for parenchymal disease, 4 years for ventricular disease, and 8 years for subarach-noid disease. Our findings can inform epidemiologic mod-els that rely on serosurveys to estimate disease burden.
原文链接
分享
引用
